Journal of Neurology Neurosurgery & Psychiatry · 2013 · 100 citations · 37 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyNeuropharmacologyPharmacodynamicsMedication Effects On VisionNeuromuscular BlockadeNeuromuscular Blocking AgentsNeuromuscular Control AssessmentNeuromuscular RehabilitationOcular PharmacodynamicsDouble-blind TrialsDownbeat NystagmusNystagmus DisordersOcular Motility TestingPatient Satisfaction AnalysisPatient Satisfaction EvaluationPostural Stability AssessmentSlow Phase Velocity Measurement
OBJECTIVE: The effects of 4-aminopyridine (4-AP) on downbeat nystagmus (DBN) were analysed in terms of slow-phase velocity (SPV), stance, locomotion, visual acuity (VA), patient satisfaction and side effects using standardised questionnaires. METHODS: Twenty-seven patients with DBN received 5 mg 4-AP four times a day or placebo for 3 days and 10 mg 4-AP four times a day or placebo for 4 days. Recordings were done before the first, 60 min after the first and 60 min after the last drug administration. RESULTS: SPV decreased from 2.42 deg/s at baseline to 1.38 deg/s with 5 mg 4-AP and to 2.03 deg/s with 10 mg 4-AP (p<0.05; post hoc: 5 mg 4-AP: p=0.04). The rate of responders was 57%. Increasing age correlated with a 4-AP-related decrease in SPV (p<0.05). Patients improved in the 'get-up-and-go test' with 4-AP (p<0.001; post hoc: 5 mg: p=0.025; 10 mg: p<0.001). Tandem-walk time (both p<0.01) and tandem-walk error (4-AP: p=0.054; placebo: p=0.059) improved under 4-AP and placebo. Posturography showed that some patients improved with the 5 mg 4-AP dose, particularly older patients. Near VA increased from 0.59 at baseline to 0.66 with 5 mg 4-AP (p<0.05). Patients with idiopathic DBN had the greatest benefit from 4-AP. There were no differences between 4-AP and placebo regarding patient satisfaction and side effects. CONCLUSIONS: 4-AP reduced SPV of DBN, improved near VA and some locomotor parameters. 4-AP is a useful medication for DBN syndrome, older patients in particular benefit from the effects of 5 mg 4-AP on nystagmus and postural stability.
37
Effects of ablation of flocculus and paraflocculus of eye movements in primate
David S. Zee, A Yamazaki, Paul Butler et al. · Journal of Neurophysiology · 1981 · 855 citations
The Timed Get-up-and-Go test revisited: measurement of the component tasks.
James C. Wall, Christopher Bell, Stephen D. Campbell et al. · PubMed · 2000 · 319 citations
Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine
Michael Strupp, R. Kalla, Martin Dichgans et al. · Neurology · 2004 · 252 citations
Treatment of downbeat nystagmus with 3,4-diaminopyridine
Michael Strupp, Olaf G. Schüler, S. Krafczyk et al. · Neurology · 2003 · 244 citations
Medicine, Neurology, Pharmacology +15